Derek McMinn
Professor Derek McMinn is a British orthopaedic surgeon and inventor who practises in Birmingham, United Kingdom at the BMI Edgbaston Hospital. Prof. McMinn developed the first successful modern metal-on-metal hip resurfacing and the instrumentation and surgical technique to implant it. Hip resurfacing is a bone-conserving, less invasive alternative to total hip replacement (THR) for young patients, markedly improves the health-related quality of life measures and currently makes up around a tenth of all hip arthroplasty (artificial joint) procedures performed in the United Kingdom. McMinn is also the inventor of several other prostheses for the  hip and knee. Derek McMinn is the author of "Modern Hip Resurfacing" (), published in 2009. Hip Resurfacing. Birmingham Hip Resurfacing. Prof. McMinn first began performing hip resurfacing procedures in 1991 using the McMinn Resurfacing. The rationale behind the procedure was that it would be a bone-conserving alternative to THR for patients with higher activity demands i.e. young patients with severe hip arthritis who are otherwise in good health. This would buy time until they reached an age at which they would be more suitable for a THR. THRs utilise small diameter metal-on-polyethylene bearings which have a high  rate of dislocation and revision in this group of patients. Sir John Charnley originally developed the conventional THR in the 1950s, which proved to be one of the most successful operations in the world. In this procedure the 'ball' part of the hip joint (femoral head) and a portion of its neck are removed and the 'socket' part (acetabulum) is grated in preparation. These are replaced with an artificial ball and socket with a long stem in the thigh bone. This and other designs of THRs have since transformed the quality of life of millions of old patients with severe  hip arthritis. Because these devices contained polyethylene as one of the rubbing surfaces, Charnley was justifiably very wary of using it in young patients. He warned against the use of a THR in any young patient unless there were other physical restraining factors which would stop her/him from getting back to high activity levels. True to his prediction when these THRs were used in young patients they failed early even in the best centres on the world, including Charnley's own centre at Wrightington Hospital in the UK. The Swedish Hip Register shows that in young patients, 19% of  THRs failed 10 years after the operation and 67% had failed by 16 years. Because these patients are young, early failure implies the need for repeated revision operations using progressively more invasive and more complex devices. It was therefore always attractive to surgeons to employ a bone conserving procedure in young patients initially. When they need a revision there is more useful bone preserved to fix the new device to. McMinn's technique of resurfacing employs thin (3–4 mm) metal surfaces to line the patients' own hip. In contrast to a THR, the femoral head and neck are retained in  this procedure. These large diameter resurfacings match the patient's own anatomy. Because they do not contain polyethylene, these bearings wear at a much lower rate, provided they are manufactured according to specifications, and are implanted well. These allow the patients to return to higher levels of activity after the operation without the fear of early wear. Furthermore, because the devices have the same diameter as the patients' own, they are less prone to dislocation. Over the following years, McMinn further improved the design and operative technique, eventually developing the Birmingham Hip Resurfacing (BHR). The first BHR was implanted in  July 1997, in Birmingham, England. Over the next few years its success spurred surgeons all over the United Kingdom, Europe, Australia and many parts of Asia to start performing the procedure. On 9 May 2006, the FDA approved the BHR for medical use in the United States. Following thirteen years of usage McMinn reports 96% success with his BHRs in all patients and all diagnoses. These resurfacings are particularly successful in young patients who are the worst group for THRs. His success rate of the BHR in this age group is 98% at 13 years. Several other series and national  registers also show similar results of around 95% currently with the BHR. The 2009 Australian National Joint Replacement Registry reported a 95% success rate for the BHR. Short Stem Hip Replacement. Birmingham Mid Head Resection. In the early 2000s, McMinn found that the results of the BHR are excellent in all types of hip arthritis except one. In a condition called osteonecrosis, in which the ball part of the hip joint suffers a loss of blood supply and becomes non-viable, the results of hip resurfacing are not good (less than 90% success 10 years after their operation). Osteonecrosis can  occur from a variety of reasons including fracture of the femoral neck, or patients who received high dose steroids due to any medical condition or those suffering from alcohol abuse. In such patients the quality of bone in the femoral head (the ball part of the hip) is compromised and progressively crunches leading to a failure of resurfacing. For such patients with poor quality femoral head bone stock, who are unsuitable for a regular hip resurfacing, McMinn developed a conservative and more versatile metal-on-metal arthroplasty, the Birmingham Mid Head Resection (BMHR) device. The BMHR is demonstrating good medium  term results in such high risk patients. Total Knee Replacement. Birmingham Knee Replacement. Derek McMinn describes himself as primarily a knee surgeon who digressed into hip surgery for a few years in the past couple of decades. His colleagues acknowledge him as one of the finest knee surgeons in the world. In addition to performing many complex primary and revision knee operations in the past three decades, he also designed and developed a revision total knee replacement (TKR) for extensive bone loss in the mid 1990s. Current evidence shows that although knee replacements survive almost as long as hip replacements , the outcome of available designs of knee replacements are not as good as hip replacements. While only 1 to 5% of patients with a THR or a hip resurfacing are unhappy with their outcomes in the early years, nearly 20% of patients who undergo a knee replacement are dissatisfied with their outcome. In an attempt to improve the functional outcome following knee replacements McMinn developed a high performance knee which closely mimics the movement, stability and function of the natural knee to a greater extent. The world-class laboratory where the BKR was bench-tested reported that of all the  artificial knees tested thus far, the BKR generated the least volume of wear. Early outcomes with the Birmingham Knee Replacement (BKR) are very promising. Of course only time will tell if the long-term satisfaction of patients with BKRs match those with hip resurfacings. Career. Derek McMinn went to Royal School Dungannon, Northern Ireland where he captained the 1st XV rugby team and represented Ulster Schools XV. He qualified from St Thomas' Hospital Medical school in London in 1977, having captained the 1st XV rugby team and won the Cheselden medal and 1st prize in surgery. He has practised as  a Consultant Orthopaedic Surgeon since 1988. McMinn personally trains surgeons from around the world in operative techniques. He is frequently invited to lecture at academic conferences around the world. He was given the honour of delivering the Presidential Guest Lecture at the Hip Society Open Meeting during the 75th Anniversary Meeting of the American Academy of Orthopaedic Surgeons in San Francisco in 2008. McMinn was also invited to deliver the 2008 Sir John Charnley Lecture at the British Orthopaedic Association and the 2008 Sir Robert Jones Lecture at the New York University Hospital for Joint Diseases in New York City , USA. In addition he has delivered guest lectures at conferences in various countries from Japan to Australia to the Asia Pacific Orthopaedic Association, the European Federation of Orthopaedic Societies, the American Academy, the Argentinian Orthopaedic Association etc. He has addressed the Select Committee of the House of Commons in the United Kingdom apprising the members of parliament and senior civil servants of recent developments and strategies of healthcare as it applies to orthopaedics. McMinn has published extensively on the topic of hip arthritis and several other related orthopaedic topics. Recently he released a book entitled Modern Hip Resurfacing, which covers  the development of resurfacing; and describes in detail all the nuances of the operative technique, in addition to being a treatise on the whole subject of resurfacing and its effects. In 2009, in recognition of his contribution to the medical profession, McMinn was awarded the degree of Doctor of Medicine (MD) Honoris Causa by the University of Birmingham. Bone samples investigation. In March 2019 a routine pathology audit in Edgbaston Hospital discovered 20 pots of bones dating back to December 2018 in a storage area. The next day senior managers arranged for staff working for him to take the samples  to the McMinn Centre nearby. An internal BMI Healthcare report found McMinn had no approval for research - required by the Human Tissue Act - nor had he carried out research on the material. The report said that the hospitals's executive director told McMinn at the start of July 2019, warning him that the hospital did not have a licence to store human tissue and that in future samples should be removed from the hospital on the day of surgery. The Care Quality Commission investigated a few weeks later and learned about the pots discovered in March. In August 2019 the  CQC asked the hospital to confirm it had a licence from the Human Tissue Agency and that McMinn had obtained consent from patients. After this McMinn was asked to justify his actions. He emailed the hospital that month, admitting "the samples were to be used for research, that he had been collecting tissue for 25 years, that he obtained verbal consent and that he had several thousand labelled samples in formalin pots with the corresponding notes, X-rays and investigations". He was suspended that month by BMI Healthcare, who informed the General Medical Council and Human Tissue Authority, though there  are no GMC restrictions on his licence to practice as of September 2020. McMinn admitted to keeping patient bones at his farmhouse in Worcestershire and his premises in Birmingham with full knowledge of his colleagues in BMI Healthcare. He said he was keeping the bone samples for his retirement, with hospital staff telling the investigation the samples had been intended "to keep his mind active". West Mercia Police confirmed that they had searched a private premises in Worcestershire while investigating an alleged breach of the Human Tissue Act after being referred to it by the Human Tissue Authority. The internal  report was unable to verify the number of samples, though they were told by McMinn's staff that there were 5,224. On 30 September 2020 BMI Healthcare launched a helpline for his patients, listing the number on their website.